# PubMed Agent Query Result

**Generated:** 2025-11-08 00:05:24

## Metadata

- **Question:** å¸®æˆ‘è¾“å‡ºä¸€ä¸ªé¢å‘èƒ°è…ºç™Œæ‚£è€…çš„ä¸€çº¿æ²»ç–—ç°ä»£åŒ–æ–¹æ¡ˆçš„ç»¼è¿°ï¼Œè¾“å‡ºåˆ°æ ¹ç›®å½•å³å¯
- **Status:** [SUCCESS]
- **Language:** chinese
- **Prompt Type:** therapeutic
- **Thread ID:** `0e1b1315-919b-44b4-81d4-c40bb4a7ed42`

## Answer

åŸºäºæˆ‘æ£€ç´¢åˆ°çš„æƒå¨åŒ»å­¦æ–‡çŒ®ï¼Œæˆ‘ç°åœ¨ä¸ºæ‚¨æ•´ç†ä¸€ä»½é¢å‘èƒ°è…ºç™Œæ‚£è€…çš„ä¸€çº¿æ²»ç–—ç°ä»£åŒ–æ–¹æ¡ˆç»¼è¿°ï¼š

# **èƒ°è…ºç™Œä¸€çº¿æ²»ç–—ç°ä»£åŒ–æ–¹æ¡ˆç»¼è¿°**

## **ã€æ ¸å¿ƒæ²»ç–—é€‰æ‹©ã€‘**

### **1. ç»å…¸åŒè¯æ–¹æ¡ˆï¼šç™½è›‹ç™½ç»“åˆç´«æ‰é†‡ + å‰è¥¿ä»–æ»¨**

- **ç–—æ•ˆæ•°æ®**ï¼š
  - ä¸­ä½æ€»ç”Ÿå­˜æœŸï¼š8.5-9.0ä¸ªæœˆ
  - 1å¹´ç”Ÿå­˜ç‡ï¼š35-38%
  - å®¢è§‚ç¼“è§£ç‡ï¼š23-31%

- **é€‚ç”¨äººç¾¤**ï¼š
  - è½¬ç§»æ€§æˆ–å±€éƒ¨æ™šæœŸèƒ°è…ºç™Œ
  - ä½“èƒ½çŠ¶æ€è¾ƒå¥½ï¼ˆECOG 0-1ï¼‰çš„æ‚£è€…
  - å¹´é¾„è¾ƒå¤§æˆ–ä¸èƒ½è€å—ä¸‰è¯æ–¹æ¡ˆçš„æ‚£è€…

### **2. å¼ºåŒ–ä¸‰è¯æ–¹æ¡ˆï¼šFOLFIRINOX**

- **ç–—æ•ˆæ•°æ®**ï¼š
  - ä¸­ä½æ€»ç”Ÿå­˜æœŸï¼š11.1-11.7ä¸ªæœˆ
  - 1å¹´ç”Ÿå­˜ç‡ï¼š48-50%

- **é€‚ç”¨äººç¾¤**ï¼š
  - å¹´è½»æ‚£è€…ï¼ˆ<65å²ï¼‰
  - ä½“èƒ½çŠ¶æ€å¥½ï¼ˆECOG 0-1ï¼‰
  - æ— ä¸¥é‡åˆå¹¶ç—‡

## **ã€ç–—æ•ˆå¯¹æ¯”åˆ†æã€‘**

æ ¹æ®2024å¹´ã€ŠLancet Oncologyã€‹å‘è¡¨çš„ç½‘ç»œèŸèƒåˆ†æï¼ˆMastrantoni et al., 2024ï¼‰ï¼š

| æ²»ç–—æ–¹æ¡ˆ | ä¸­ä½OSï¼ˆæœˆï¼‰ | 1å¹´ç”Ÿå­˜ç‡ | ä¸»è¦å‰¯ä½œç”¨ |
|---------|--------------|------------|-------------|
| **FOLFIRINOX** | 11.1-11.7 | 48-50% |
| **ç™½è›‹ç™½ç´«æ‰é†‡+å‰è¥¿ä»–æ»¨** | 8.5-9.0 | 35-38% |
| **NALIRIFOX** | 10.5-12.0 | 45-52% |
| **å‰è¥¿ä»–æ»¨å•è¯** | 6.8-7.0 | 22-25% |

**å…³é”®å‘ç°**ï¼š
- FOLFIRINOXç›¸æ¯”å‰è¥¿ä»–æ»¨å•è¯ï¼Œä¸­ä½ç”Ÿå­˜æœŸå»¶é•¿çº¦4-5ä¸ªæœˆ
- 1å¹´ç”Ÿå­˜ç‡å‡ ä¹ç¿»å€

## **ã€ç²¾å‡†åŒ»ç–—æ–°çªç ´ã€‘**

### **PARPæŠ‘åˆ¶å‰‚ï¼šå¥¥æ‹‰å¸•åˆ©ï¼ˆOlaparibï¼‰**

- **é€‚ç”¨äººç¾¤**ï¼š
  - **BRCA1/2åŸºå› çªå˜**æ‚£è€…
  - çº¦å èƒ°è…ºç™Œæ‚£è€…çš„5-7%
  - éœ€è¦åŸºå› æ£€æµ‹ç¡®è®¤

- **ç–—æ•ˆæ•°æ®ï¼ˆPOLOè¯•éªŒï¼‰**ï¼š
  - ç»´æŒæ²»ç–—ä¸­ä½æ— è¿›å±•ç”Ÿå­˜æœŸï¼š7.4ä¸ªæœˆ vs 3.8ä¸ªæœˆï¼ˆå®‰æ…°å‰‚ï¼‰
  - ç–¾ç—…è¿›å±•é£é™©é™ä½47%

- **æ²»ç–—æ–¹æ¡ˆ**ï¼š
  - ä¸€çº¿é“‚ç±»åŒ–ç–—è‡³å°‘16å‘¨ä¸”ç–¾ç—…æœªè¿›å±•
  - åç»­ä½¿ç”¨å¥¥æ‹‰å¸•åˆ©ä½œä¸ºç»´æŒæ²»ç–—

## **ã€æ²»ç–—å†³ç­–è€ƒé‡å› ç´ ã€‘**

### **1. æ‚£è€…ä¸ªä½“ç‰¹å¾**ï¼š
- **å¹´é¾„**ï¼šå¹´è½»æ‚£è€…æ›´é€‚åˆFOLFIRINOX
- **ä½“èƒ½çŠ¶æ€**ï¼šECOG 0-1å¯è€ƒè™‘å¼ºåŒ–æ–¹æ¡ˆ
  - åˆå¹¶ç—‡æƒ…å†µ
  - åŸºå› çªå˜çŠ¶æ€

### **2. å‰¯ä½œç”¨ç®¡ç†**ï¼š

**ç™½è›‹ç™½ç´«æ‰é†‡+å‰è¥¿ä»–æ»¨**ï¼š
- ç¥ç»æ¯’æ€§ï¼ˆå‘ç”Ÿç‡20-25%ï¼‰
- éª¨é«“æŠ‘åˆ¶

**FOLFIRINOX**ï¼š
- è…¹æ³»ã€æ¶å¿ƒã€å‘•å
- ä¸­æ€§ç²’ç»†èƒå‡å°‘

## **ã€æ–°ç–—æ³•å‰æ²¿ã€‘**

### **1. NALIRIFOXæ–¹æ¡ˆ**ï¼š
- è„‚è´¨ä½“ä¼Šç«‹æ›¿åº· + æ°Ÿå°¿å˜§å•¶ + å¥¥æ²™åˆ©é“‚
- èƒƒè‚ é“æ¯’æ€§è¾ƒé‡

## **ã€æœªæ¥å±•æœ›ã€‘**

### **ç²¾å‡†åŒ»ç–—æ–¹å‘**ï¼š
- **BRCAçªå˜**ï¼šå¥¥æ‹‰å¸•åˆ©ç»´æŒæ²»ç–—
- **NTRKèåˆ**ï¼šæ‹‰ç½—æ›¿å°¼ç­‰é¶å‘è¯ç‰©
- **MSI-H**ï¼šå…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚

### **ä¸´åºŠè¯•éªŒæœºä¼š**ï¼š
- å¤šç§PARPæŠ‘åˆ¶å‰‚ç ”ç©¶è¿›è¡Œä¸­
- è”åˆæ²»ç–—ç­–ç•¥æ¢ç´¢

## **ã€é‡è¦åŒ»å­¦å£°æ˜ã€‘**

> **æœ¬ç»¼è¿°åŸºäºPubMedåŒ»å­¦æ•°æ®åº“çš„æƒå¨ä¸´åºŠç ”ç©¶ï¼Œæ—¨åœ¨å¸®åŠ©æ‚£è€…å’Œå®¶å±äº†è§£èƒ°è…ºç™Œä¸€çº¿æ²»ç–—çš„ç°ä»£åŒ–æ–¹æ¡ˆã€‚æ¯ä½æ‚£è€…çš„æƒ…å†µéƒ½æ˜¯ç‹¬ç‰¹çš„ï¼Œå…·ä½“çš„æ²»ç–—æ–¹æ¡ˆå¿…é¡»ç”±æœ‰èµ„è´¨çš„è‚¿ç˜¤ç§‘åŒ»ç”Ÿæ ¹æ®å…·ä½“ç—…æƒ…åˆ¶å®šã€‚**

---

**å®Œæ•´å‚è€ƒæ–‡çŒ®**ï¼š

1. **Ozaka, M., et al. (2023).** A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). *European Journal of Cancer*, 181, 135-144. PMID: 36652891

2. **Mastrantoni, L., et al. (2024).** Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis. *Lancet Oncology*, 25(12), 1655-1665. PMID: 39542008

3. **Golan, T., et al. (2019).** Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *New England Journal of Medicine*, 381(4), 317-327. PMID: 31157963

4. **Kindler, H. L., et al. (2022).** Overall Survival Results From the POLO Trial: A Phase III Study. *Journal of Clinical Oncology*, 40(34), 3929-3939. PMID: 35834777

5. **Chiorean, E. G., et al. (2019).** Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer. *Therapeutic Advances in Medical Oncology*, 11, 1758835919850367. PMID: 31205510

**è¯æ®ç­‰çº§è¯´æ˜**ï¼š
- ğŸ”¬ **å¤§å‹ä¸´åºŠè¯•éªŒ**ï¼šPOLOã€MPACTç­‰
- ğŸ“Š **èŸèƒåˆ†æ**ï¼šæœ€é«˜è¯æ®ç­‰çº§
- ğŸ” **çœŸå®ä¸–ç•Œç ”ç©¶**ï¼šåæ˜ ä¸´åºŠå®è·µæ•ˆæœ

---

**æ­¤ç»¼è¿°å·²ä¿å­˜è‡³æ ¹ç›®å½•ï¼ŒåŒ…å«æœ€æ–°çš„èƒ°è…ºç™Œä¸€çº¿æ²»ç–—å¾ªè¯åŒ»å­¦è¯æ®ï¼Œä¸ºæ‚£è€…å’ŒåŒ»ç”Ÿæä¾›å…¨é¢çš„æ²»ç–—å†³ç­–å‚è€ƒã€‚**
